Genetic Evidence for Elevated Pathogenicity of Mitochondrial DNA Heteroplasmy in Autism Spectrum Disorder by Wang, Yiqin et al.
RESEARCH ARTICLE
Genetic Evidence for Elevated Pathogenicity
of Mitochondrial DNA Heteroplasmy in
Autism Spectrum Disorder
Yiqin Wang1, Martin Picard2,3, Zhenglong Gu1*
1 Division of Nutritional Sciences, Cornell University, Ithaca, New York, United States of America,
2 Department of Psychiatry, Division of Behavioral Medicine, Columbia University Medical Center, New
York, New York, United States of America, 3 Department of Neurology, Division of Columbia Translational
Neuroscience Initiative, Columbia University Medical Center, New York, New York, United States of America
* zg27@cornell.edu
Abstract
Increasing clinical and biochemical evidence implicate mitochondrial dysfunction in the
pathophysiology of Autism Spectrum Disorder (ASD), but little is known about the biological
basis for this connection. A possible cause of ASD is the genetic variation in the mitochon-
drial DNA (mtDNA) sequence, which has yet to be thoroughly investigated in large genomic
studies of ASD. Here we evaluated mtDNA variation, including the mixture of different
mtDNA molecules in the same individual (i.e., heteroplasmy), using whole-exome sequenc-
ing data from mother-proband-sibling trios from simplex families (n = 903) where only one
child is affected by ASD. We found that heteroplasmic mutations in autistic probands were
enriched at non-polymorphic mtDNA sites (P = 0.0015), which were more likely to confer
deleterious effects than heteroplasmies at polymorphic mtDNA sites. Accordingly, we
observed a ~1.5-fold enrichment of nonsynonymous mutations (P = 0.0028) as well as a
~2.2-fold enrichment of predicted pathogenic mutations (P = 0.0016) in autistic probands
compared to their non-autistic siblings. Both nonsynonymous and predicted pathogenic
mutations private to probands conferred increased risk of ASD (Odds Ratio, OR[95% CI] =
1.87[1.14–3.11] and 2.55[1.26–5.51], respectively), and their influence on ASD was most
pronounced in families with probands showing diminished IQ and/or impaired social behav-
ior compared to their non-autistic siblings. We also showed that the genetic transmission
pattern of mtDNA heteroplasmies with high pathogenic potential differed between mother-
autistic proband pairs and mother-sibling pairs, implicating developmental and possibly in
utero contributions. Taken together, our genetic findings substantiate pathogenic mtDNA
mutations as a potential cause for ASD and synergize with recent work calling attention to
their unique metabolic phenotypes for diagnosis and treatment of children with ASD.
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Author Summary
Mitochondria contain their own genome, the mitochondrial DNA (mtDNA), and are
abundant in the brain where they produce energy and intracellular signals required for
normal brain function and cognition.Mitochondrial dysfunction has been proposed as a
cause of Autism SpectrumDisorder (ASD), but the genetic basis has not been established.
By analyzing mtDNA sequences from 903 ASD children along with their unaffected sib-
lings and mothers, we found a unique pattern of heteroplasmic mtDNA mutations (the
coexistence of both mutant and wide-typemtDNA molecules in a cell) associated with
increased risk of ASD. A large fraction of these mtDNA heteroplasmies are pathogenic
and can be either inheritedmaternally or acquired during development. Our findings
unveil an important issue about pathogenic mtDNA heteroplasmy transmission between
mothers and children, which could underlie many neurodevelopmental disorders in chil-
dren that are shown to involve mitochondrial dysfunction. Evaluating mtDNA heteroplas-
mies in high-risk families could help diagnosis and treatment of these diseases.
Introduction
Autism SpectrumDisorder (ASD) refers to a broad collection of complex, neurodevelopmental
disorders, characterized by impairment of communicative and social interactions [1]. ASD
usually manifests at an early stage of development in pre-pubertal children [2]. The current
prevalence of ASD in the United States according to the 2014 annual report from The Centers
for Disease Control and Prevention (CDC) is 1 in 68 children (1.47%), with a skewed gender
ratio of 4 affected boys to 1 affected girl [3]. Population-based studies suggest an even higher
prevalence of 2.24% in the United States [4]. Treatment for ASD mostly relies on behavioral
interventions with specialized training to lessen social, verbal and cognitive deficits. However,
the effectiveness varies widely among children with ASD and mild forms of symptoms such as
attention deficit and social difficultiesmay persist throughout life [5].
Although ASD is traditionally described as a developmental disorder of the central nervous
system, emerging evidence suggests that systemic physiological abnormalities, including dysre-
gulated inflammation and immune system [6,7], elevated oxidative stress [8], and mitochon-
drial dysfunction [9–12], are present in peripheral tissues as well as in brains of autistic
patients [13]. Epidemiological studies also identified a staggeringly high comorbidity between
ASD and mitochondrial disorder (MD) [14]. MD is a heterogeneous group of diseases due to
maternally inherited or sporadic defects in genes encoding the mitochondrial oxidative phos-
phorylation (OXPHOS) system [15], the core functional component of mitochondria responsi-
ble for generating energy. MD usually results from genetic mutations on nuclear DNA or
mitochondrial DNA (mtDNA) genes [15]. It has an extremely low birth prevalence of 6.2 in
100,000 children [16] and only about 1 in 4,300 adults is affected or at risk of developingMD
[17]. However, the incidence of MD among autistic patients is estimated up to 5% by some
studies [14], over 200-fold the incidence of MD in general populations. In addition, expression
of OXPHOS genes has been shown to decrease in brains of autistic patients [18], suggesting a
biological overlap in the pathogenesis of MD and ASD. Moreover, decreased activity of the five
OXPHOS complexes has been observed in leukocytes, buccal cells, muscle biopsies and brains
of autistic patients [11,14,19], suggesting the increasedMD incidence among autistic patients
is due not to a specific protein defect but to defects across components of the OXPHOS system.
Notwithstanding ever-growing evidence implicating mitochondrial dysfunction in the
pathophysiology of ASD, little is known about the biological basis of this connection [19].
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Polymorphisms in genes in mitochondria-related pathways, such as PARK2 [20] and
SLC25A12 [21], were previously found to be associated with ASD in genome-wide or candidate
gene association studies, suggesting a genetic basis. However, in recent comprehensive genetic
studies among over two thousand affected families, few of the identified risk loci for ASD har-
bor genes showing a direct link with mitochondrial function [22–25]. The results from
mtDNA studies are also mixed. A number of studies demonstrated elevation of mtDNA dele-
tions [10,26], point mutations [9,26,27], or copy numbers [10,28] in autistic patients. Interest-
ingly, increasedmtDNA copy number can occur secondarily to mitochondrial defects [29],
further indicating the presence of genetic and/or functional defects in ASD. But few of these
findings have been confirmed in large populations [30].
Because there are thousands of mtDNA molecules in a single cell, newmutations can arise
and coexist with the wide-typemtDNA in a state called heteroplasmy, which has been impli-
cated in a wide range of diseases [31,32]. To evaluate mtDNA heteroplasmy among healthy
individuals, next-generation sequencing technologies such as mtDNA-targeted sequencing
[33–36] or computational approaches, which directly leverage (off-target) reads from existing
datasets produced by whole-genome sequencing [37,38] or whole-exome sequencing [39,40]
have been widely harnessed in recent years. These approaches largely outperform Sanger
sequencing and microarray-based sequencing in their ability to detect mtDNA heteroplasmies,
and have proven practical for large population-based studies [37–39].
In the current study, we investigated the connection betweenmtDNA variation, especially
heteroplasmy, and ASD by leveraging off-target reads from exome-sequencing data sets among
simplex families from the Simons Foundation Autism Research Initiative (SFARI) Simons Col-
lection deposited at the National Autism Research Database [23]. Each simplex family is com-
posed of one autistic proband, his or her non-autistic sibling and their parents. Because the
proband and the sibling have the same mtDNA background, share family environment, and
are of comparable age, our study avoids genetic and environmental confounding factors that
have limited the interpretation of studies among unrelated case-control pairs or child-parent
pairs [30]. Given that the mtDNA is maternally inherited, we analyzed data for mother-pro-
band-sibling trios from 903 simplex families and utilized stringent criteria to determine
mtDNA homoplasmies and heteroplasmies. We then compared mtDNA variation between
autistic probands and non-autistic siblings, along with the transmission pattern of mtDNA
mutations between the mother and the child. We showed that autistic children have overrepre-
sented pathogenic mutations on mtDNA distinct from their unaffected siblings. Our results
offer an important angle to explain mitochondrial dysfunction in ASD patients, pointing
towards the accumulation of mtDNA mutations of high pathogenic potential during develop-
ment as one possible mechanism underlying the metabolic pathophysiology of ASD.
Results
Characteristics of mtDNA variants in the studied families
The whole-exome sequencing data for the SFARI Simons Collectionwere generated by three
genome centers including CSHL (Cold Spring Harbor Laboratory), YALE (the Department of
Genetics at the Yale School of Medicine) and UW (Genome Sciences at the University of
Washington) [23]. Only reads generated by CSHLmet our minimal mtDNA sequence cover-
age depth, where reads from YALE and UW yielded on average less than 20% of mtDNA sites
sequenced to>20X depth (S1 Fig). Hence, this study focused on the 933 families sequenced at
CSHL. After quality control, we obtained data for mother-proband-sibling trios from 903 fami-
lies, or 2,709 individuals. The average depth of sequencing coverage on mtDNA was 141X,
which allowed us to call homoplasmies and medium-fractionheteroplasmies.
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We first examined the distribution of mtDNA variants. In total, we identified 68,670 homo-
plasmies according to the revisedCambridge Reference Sequence (rCRS) at 2,152 mtDNA
polymorphic sites. Among them, up to 1,847 (85.8%) sites showed the minor allele in less than
1% of individuals, and 1,031 (47.9%) sites were unique to individual families (S2 Fig). When fil-
tering high-confidenceheteroplasmies at minor allele fraction (MAF)5%, we identified 677
heteroplasmies at 366 mtDNA sites. Based on this stringent criterion to define heteroplasmy,
approximately 21.1% of individuals carried at least one heteroplasmy on mtDNA. Individual
(n = 229, 62.6%) or family (n = 323, 88.3%) specific heteroplasmies contributed to the majority
of the heteroplasmic sites detected (S2 Fig). Only one heteroplasmy, located at position 16,093
in the D-loop region, was present in1% of individuals.
Consistent with our previous findings in the 1000 Genomes population [37,41], we found
strong evidence to support the extensive purifying selection on mtDNA. For both homoplas-
mies and heteroplasmies, their nonsynonymous-synonymous rate ratio was significantly less
than one (P<5x10-19, Fig 1A); their pathogenic potential at nonsynonymous sites was consid-
erably lower than that of all possible, nonsynonymous nucleotide substitutions on mtDNA
(P<2x10-14, Fig 1B). Of note, compared to homoplasmies, heteroplasmies exhibited higher
nonsynonymous-synonymous rate ratio (P = 1.2x10-11, Fig 1A), along with elevated pathoge-
nicity at nonsynonymous sites (P = 1.5x10-4, Fig 1B). This may be due to mitochondrial thresh-
old effect [42], which masks deleterious phenotypes of low-fractionmtDNA heteroplasmies,
allowing them to persist without being purged by natural selection.
We found that 194 (53.0%) heteroplasmic sites were located at polymorphic sites. Interest-
ingly, only heteroplasmies at non-polymorphic sites exhibited inflated pathogenicity compared
to homoplasmies (P<1.7x10-6, Fig 1C and 1D). mtDNA heteroplasmies at non-polymorphic
sites also possessed very low relative mutation rates (S3 Fig). Both features impeded the intro-
duction of these mutations into the phylogenetic tree; low mutation rates were responsible for
the rare occurrence of these mutations in the first place; if they did mutate and appeared ini-
tially in the heteroplasmic state, purifying selectionwould act on them as soon as the mutant
allele fraction exceeded the mitochondrial threshold for manifesting the associated, deleterious
phenotype affecting survival or reproduction. The opposite case lies in the mtDNA mutations
that have been shown to have entered the phylogenetic tree multiple times, demonstrating low
pathogenicity and high relative mutation rates [43]. In comparison with homoplasmies at non-
heteroplasmic sites, heteroplasmies at polymorphic sites exhibited similar level of pathogenic-
ity (Fig 1C and 1D), but were more likely to mutate (Mann-Whitney test, P = 8x10-32, S3 Fig),
suggesting their high incidence of being heteroplasmic may be primarily the consequence of
their inherent, high mutation rates.
Elevated pathogenicity of mtDNA mutations in autistic probands
Given evidence on mitochondrial implication in ASD, we postulated that autistic probands
might carrymutation burden on mtDNA, especiallymutations prone to confer deleterious
effects on OXPHOS. To test this hypothesis, we directly compared the number as well as the
distribution of mtDNA mutations, at segregating sites within each family, between autistic pro-
bands and their non-autistic siblings. For this comparison, we analyzed mtDNA sites where all
members in a family had>40X sequencing depth. Among the 903 families, 191 autistic pro-
bands (21.2%) and 182 non-autistic siblings (20.2%) carried at least one high-confidencehet-
eroplasmic or homoplasmic mutation with derived allele fraction (DAF) 5% (referred to
throughout as mutation). On average, autistic probands carried 0.25 mutations and their non-
autistic siblings carried 0.24 mutations, indicating the overall mutation burden was not signifi-
cantly different between these two groups (P = 0.3, Fig 2A). However, heteroplasmic mutations
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were more likely to be located at non-polymorphic sites in autistic probands than those in non-
autistic siblings (Chi-squared test, P = 0.0015). The incidence of heteroplasmic mutations at
non-polymorphic sites was 53% higher in autistic probands compared to non-autistic siblings
(0.11 per proband vs. 0.072 per sibling, P = 0.0003, Fig 2A).
Because the observedpathogenicity of mtDNA mutations was primarily attributed to het-
eroplasmies at non-polymorphic sites (Fig 1C and 1D), overrepresented mutations at non-
polymorphic sites might imply an elevated pathogenicity. As expected, further stratifying
Fig 1. Characteristics of mtDNA variants. (A) The nonsynonymous-synonymous rate ratio (hN/hS) for all
possible nucleotide substitutions, observed heteroplasmies, and homoplasmies on mtDNA. hN is the number of
nonsynonymous substitutions divided by the total number of possible nonsynonymous substitutions on mtDNA;
similarly, hS is the number of synonymous substitutions divided by the total number of possible synonymous
substitutions on mtDNA [34]. The ratio of hN and hS is indicative of purifying selection if it is significantly less than
one [34]. (B) The box plot of CADD pathogenicity scores for all possible substitutions, observed heteroplasmies
and homoplasmies at nonsynonymous sites on mtDNA. (C, D) hN/hS (C) and CADD pathogenicity scores of
nonsynonymous substitutions (D) for heteroplasmies at non-polymorphic sites, heteroplasmies at polymorphic
sites and homoplasmies at non-heteroplasmic sites. Each nucleotide substitution was only counted at most once.
***P<2x10-4; **P<2x10-3; P: p values for Chi-squared test (A,C) or Mann-Whitney test (B,D).
doi:10.1371/journal.pgen.1006391.g001
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mutations according to their functional annotations revealed that autistic probands carried
52%more nonsynonymous mutations (0.084 per proband vs. 0.055 per sibling; P = 0.0028, Fig
2C), and 118%more predicted pathogenic mutations compared to non-autistic siblings (0.041
per proband vs. 0.019 per sibling; P = 0.0016, Fig 2C). Autistic probands also had roughly twice
as many mutations associatedwith disease as their non-autistic siblings had (0.012 per proband
vs. 0.006 per sibling; P = 0.017, S4 Fig). Additionally, the observed increases of pathogenic
mutations in autistic probands were insensitive to changes in minimumDAF we used for
definingmutations (from 2% to 8%, S5 Fig). In line with these results, there was no significant
evidence on mutation burden at synonymous sites as well as in the D-loop region (P>0.6, Fig
2B), which were normally considered to harbor relatively neutral variants [44].
There were 265 mtDNA mutations that were private to only one child within a family: its
derived allele was undetectable or had fraction<2% in the other child. Carryingnonsynon-
ymous private mutations was associated with an increased risk of ASD (Odds Ratio, OR: 1.87,
P = 0.0055, Table 1). Likewise, carrying private mutations of predicted pathogenicity more
than doubled the risk of ASD (OR: 2.55, P = 0.0036, Table 1). Among the 596 families whose
Fig 2. Comparison of mtDNA mutation burden and pathogenicity between autistic probands and non-
autistic siblings. Mutation burden was calculated using mutations with DAF5% at mtDNA sites where all
members in a family had >40X sequencing depth. The average number of mutations per individual was shown in
(A) for all valid sites and non-polymorphic sites, in (B) for sites in the D-loop region and synonymous sites in the
coding region, and in (C) for sites in the RNA region, nonsynonymous sites in the coding region, and mutations
predicted pathogenic with CADD Phred score >15 or >20. Results in the main text were based on “CADD > 15”.
Error bars represent the standard error of the mean. ***P<0.001; **P<0.01; *P<0.05; P: p values for one-tailed
paired t-test.
doi:10.1371/journal.pgen.1006391.g002
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ASD risk was not attributed to any de novo likely gene-disruptive (LGD) SNVs or CNVs in the
nuclear genomes [23,24], we attained comparable ORs for ASD risk at 2.00 and 2.42 for nonsy-
nonymous private mutations and pathogenic private mutations, respectively (P<0.025,
Table 1). Therefore, the observed association betweenmtDNA mutations and ASD is unlikely
to be contingent upon spontaneous nuclear gene mutations.
Pathogenic mtDNA mutations correlate with ASD-associated
phenotypes
We further sought to investigate the relationship betweenmtDNA mutations and ASD-associ-
ated phenotypes, including cognitive ability and social behavior. Compared to ORs in total
families, the ORs for ASD risk were attenuated when estimated only in families with the pro-
band classified as having normal intelligence quotient (full-scale IQ>85, referred to through-
out as IQ) (Table 1). A similar attenuated genetic contribution to ASD was also identified in
previous nuclear genome studies [23,24], suggesting a predominant role of genetic factors in
the pathogenesis of ASD only in the context of diminished IQ. Next, we retrieved the Social
Responsiveness Scale scores for probands and siblings (parent-reported total SRS T scores,
referred to throughout as SRS) in the 903 families, which is a measure of ASD severity in natu-
ral social settings.We defined families with discordant proband-sibling social behavior using
criteria according to Krumm et al. [24] where autistic probands demonstrated severe social
Table 1. Contribution of private mtDNA mutations to ASD.
Subpopulations Groups Proband a Sibling a OR [95% CI] P
All Nonsynonymous 51 (5.6%) 28 (3.1%) 1.87 [1.14–3.11] 0.0055
(n = 903 families) CADD > 15 30 (3.3%) 12 (1.3%) 2.55 [1.26–5.51] 0.0036
CADD > 20 22 (2.4%) 9 (1.0%) 2.48 [1.09–6.15] 0.014
No de novo LGD variants b Nonsynonymous 35 (5.9%) 18 (3.0%) 2.00 [1.09–3.80] 0.012
(n = 596 families) CADD > 15 19 (3.2%) 8 (1.3%) 2.42 [1.00–6.44] 0.025
CADD > 20 16 (2.7%) 7 (1.2%) 2.32 [0.89–6.72] 0.044
Normal IQ Nonsynonymous 20 (4.7%) 16 (3.7%) 1.26 [0.61–2.64] 0.31
(n = 428 families) c CADD > 15 12 (2.8%) 6 (1.4%) 2.03 [0.70–6.65] 0.12
CADD > 20 7 (1.6%) 5 (1.2%) 1.41 [0.38–5.66] 0.39
Diminished IQ Nonsynonymous 28 (6.6%) 10 (2.3%) 2.92 [1.36–6.84] 0.0021
(n = 427 families) c CADD > 15 16 (3.7%) 5 (1.2%) 3.28 [1.14–11.6] 0.012
CADD > 20 13 (3.0%) 4 (0.9%) 3.32 [1.01–14.1] 0.023
Concordant SRS Nonsynonymous 22 (5.5%) 17 (4.2%) 1.31 [0.65–2.67] 0.26
(n = 403 families) d CADD > 15 15 (3.7%) 8 (2.0%) 1.91 [0.75–5.26] 0.10
CADD > 20 11 (2.7%) 5 (1.2%) 2.23 [0.71–8.27] 0.10
Discordant SRS Nonsynonymous 29 (5.9%) 10 (2.0%) 3.02 [1.41–7.02] 0.0014
(n = 492 families) d CADD > 15 15 (3.0%) 4 (0.8%) 3.83 [1.21–16.0] 0.0090
CADD > 20 11 (2.2%) 4 (0.8%) 2.79 [0.82–12.1] 0.058
aData are the number of individuals carrying private mutations (percentage of families).
bfamilies whose ASD risk was not attributed to de novo LGD SNVs or CNVs; data on exomic de novo LGD SNPs and CNVs were obtained from references
[23,24].
cfamilies with probands having full-scale IQ >85 or85; IQ information for 48 families was not available.
dFamilies with discordant SRS scores had proband SRS score >75 and sibling SRS score <50; otherwise they were considered as having concordant SRS
scores; proband and sibling SRS scores were not available in 8 families.
CADD: mutations predicted pathogenic with CADD Phred score >15 or >20; results in the main text were based on “CADD > 15”; P: one-tailed p values for
Fisher’s exact test.
doi:10.1371/journal.pgen.1006391.t001
Pathogenic mtDNA Heteroplasmy and Autism
PLOS Genetics | DOI:10.1371/journal.pgen.1006391 October 28, 2016 7 / 24
impairments (SRS score>75) as opposed to their non-autistic siblings (SRS score<50). We
found that ORs of mtDNA mutations for ASD risk were stronger in families with discordant
SRS scores between probands and siblings than families with concordant SRS scores (Table 1),
indicating that mtDNA mutations might segregate with autistic behavioral phenotypes at a
family level.
Because behavioral impairment inversely correlated with cognitive ability in autistic pro-
bands (Pearson correlation coefficient between SRS scores and IQ, r = -0.22, P = 4.5x10-11), we
further stratified the 903 families into four groups according to the criteria on both IQ and SRS
scores. Even though the sample sizes were getting smaller in each category, the effects of
mtDNA private mutations on ASD were most significant (ORs = 3.56–4.61, Fisher’s exact test,
P<0.09, S1 Table) in families with discordant proband-sibling SRS scores and diminished pro-
band IQ, and were least pronounced (ORs = 0.90–1.77, Fisher’s exact test, P>0.27, S1 Table) in
families with concordant SRS scores and normal proband IQ, suggesting that the observedcon-
tribution of mtDNA mutations to ASD was mostly attributed to families with probands show-
ing noticeable deficits in cognition and/or social interactions distinct from their siblings.
Of note, the incidence of private mtDNA mutations was consistently higher in autistic pro-
bands of the diminished IQ group than that of the normal IQ group (3.0%–6.6% vs. 1.6%–
4.7%, Table 1). To examine whether carrying private mtDNA mutations affects cognitive abil-
ity, we further analyzed the impact of private mtDNA mutations on IQ as well as intellectual
disability (ID, which we defined as IQ<70) among autistic probands. In the 903 families, pro-
band IQ was significantly associated with family ancestry (one-way ANOVA, P<4.8x10-10). To
avoid such confounding factors on proband IQ comparisons among families, we focused on
638 probands of the major ethnic group in the current study for further analysis (S6 Fig and
Table 2). Private mtDNA mutations detected at non-polymorphic sites were significantly asso-
ciated with decreased proband IQ (linear regression, β = -7.8, P = 0.02, S6 Fig). Similar effects
on IQ were also observable for nonsynonymous and predicted pathogenic mtDNA mutations
private to probands, but the corresponding P values were not significant (β = -7.3 –-5.6,
P = 0.15–0.27, S6 Fig). A considerable decrease in IQ was identified in probands with disease-
associated private mtDNA mutations which lowered the average IQ by approximately 25
points compared to those devoid of these mutations (P = 0.01, S6 Fig).
We then asked whether the observed shift of IQ distribution could lead to comorbidity of
ASD and ID by using logistic regression.We found that mtDNA mutations at non-
Table 2. Contribution of private mtDNA mutations to ID in ASD.
Groups Model 1a Model 2 a
OR [95% CI] P OR [95% CI] P
Non-polymorphic 2.34 [1.36–4.03] 0.0022 2.41 [1.39–4.18] 0.0018
Polymorphic 1.11 [0.62–1.98] 0.72 1.06 [0.59–1.89] 0.85
Nonsynonymous 1.98 [1.03–3.78] 0.039 1.89 [0.98–3.66] 0.058
CADD > 15 2.42 [1.09–5.37] 0.031 2.35 [1.05–5.28] 0.039
CADD > 20 2.75 [1.10–6.85] 0.030 2.59 [1.04–6.45] 0.040
Disease-associated 2.59 [0.57–11.9] 0.22 2.38 [0.51–11.1] 0.27
Associations of ID (defined as full-scale IQ <70) with proband-private mtDNA mutations were computed in 638 probands of the major ethnic group among
the 903 families who had a reported family ancestry of “white” or “more-than-one-race” and an mtDNA-haplogroup inferred maternal ancestry of “Europe”.
aOR (odds ratio), 95% CI (confidence interval) of OR, and P values were computed for mutations in each category using logistic regression Model 1
(adjusting for age and sex) and Model 2 (adjusting for age, sex, SRS scores and whether carrying de novo LGD SNPs or CNVs on nuclear DNA).
CADD: mutations predicted pathogenic with CADD Phred score >15 or >20; results in the main text were based on “CADD > 15”.
doi:10.1371/journal.pgen.1006391.t002
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polymorphic sites as well as nonsynonymous and predicted pathogenic mtDNA mutations
that were private to probands significantly increased the risk of ID in ASD (ORs = 1.98–2.75,
P = 0.0022–0.039, Table 2), The estimated ORs did not qualitatively change after additional
adjustment for ASD severity (proband SRS scores) and whether carrying de novo LGD SNPs or
CNVs on nuclear DNA (Table 2). It suggests that mtDNA mutations and the resulting mito-
chondrial dysfunctionmay be responsible for intellectual disability in ASD, which is consistent
with clinical reports on ASD-ID cases whomanifested defects in mitochondrial OXPHOS [45].
Different mother-to-child mtDNA mutation transmission between autistic
probands and non-autistic siblings
BecausemtDNA is uniquely inherited from the mother [46], this dataset also provided us a
great opportunity to investigate the transmission pattern of mtDNA mutations frommothers
to children. Among all inherited events of homoplasmies from the mother to the child, 99.3%
(45,488) were direct transmissions of maternal homoplasmies, and the remaining 0.7% of
events resulted from the fixation of either the major allele (n = 295) or the minor allele (n = 6)
of maternal heteroplasmies. Among all mother-child pairs, we only identified one possible de
novo homoplasmy in a non-autistic sibling (family id: 12899), located in the D-loop region
(143G>A), whosemutant allele A was not detected in either the mother or the autistic
proband.
There was a significant correlation of derived allele fractions for heteroplasmies between the
mother and the child (Pearson correlation coefficient r = 0.38, P = 1.9x10-10). For heteroplas-
mies with MAF 5% in the child, 53.1% were shared with the mother, and therefore were
inherited, in agreement with previous studies [36,38]. The proportion of inherited heteroplas-
mies decreased to 33.7%, when we lowered the minimumMAF in calling heteroplasmies in
children to 2% (S7 Fig), indicating that a majority of heteroplasmies in children could be of
developmental origin. However, we might underestimate the proportion of inherited hetero-
plasmies, since some heteroplasmies might be of low fraction or somatically lost in the mother.
It has been shown that purifying selection operates during oogenesis and early embryogene-
sis to reduce the possibility of pathogenic mtDNA mutations being transmitted to the subse-
quent generation [47]. This mtDNA quality control mechanism ensures the OXPHOS
function in the maternal germ line and thereby in the child [48]. The influence of this purifica-
tion selection process was evidenced in our dataset with a significant decrease in the proportion
of transmitted mutations that were predicted pathogenic, compared to that of untransmitted
mutations in mother-sibling pairs (P = 0.005, Fig 3A). However, evidence of the purification
selection disappeared when computed in mother-autistic proband pairs, which might be
skewed by the ascertainment of disease status in autistic probands [49] (Fig 3B). Interestingly,
de novomutations in autistic probands showed an even higher proportion of predicted patho-
genic mutations compared to untransmitted mutations (P = 0.025, Fig 3B) in mother-autistic
proband pairs.
To ascertain the pathogenic mutation burden observed in autistic probands, we further cal-
culated the changes of derived allele fractions betweenmutations in the mother and mutations
in the child (ΔDAF = DAFchild–DAFmother). Overall,ΔDAF followed a normal distribution cen-
tered about zero for mutations in both mother-sibling pairs and mother-proband pairs (S8A
and S8B Fig), reflecting the predominant influence of genetic drift and mutation on hetero-
plasmy [49]. There were 31 out of 48 predicted pathogenic mutations that increased in DAF in
mother- autistic proband pairs, in contrast to only 13 out of 36 predicted pathogenic mutations
that increased in DAF in mother-sibling pairs (Fisher’s exact test, P = 0.015, S8E and S8F Fig).
Taken together, these results indicated that the transmission pattern of heteroplasmies of high
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pathogenic potential differed betweenmother-autistic proband pairs and mother-sibling pairs,
resulting in a greater abundance of these mutations on mtDNA in autistic children.
Discussion
By employing a set of stringent criteria in calling heteroplasmies, we found a prevalence that
21.1% of individuals carry at least one medium-to-high fraction heteroplasmy with MAF of at
least 5%. In order to draw meaningful comparisons with previous studies, we re-calculated the
prevalence of heteroplasmy by applying the sameMAF detection threshold at 5% in studies
using blood specimens. In Rebolledo-Jaramillo et al.’s study, the prevalence of heteroplasmy is
Fig 3. Transmission pattern of pathogenic mtDNA mutations. The proportion of untransmitted (red), transmitted (purple) and de novo (blue)
mutations that were nonsynonymous or predicted pathogenic was shown in (A) for mother-sibling pairs and in (B) for mother-proband pairs.
Only mtDNA sites (n = 448) detected with high-confidence heteroplasmies (MAF5%) or de novo homoplasmies were used for calculation.
Untransmitted mutations were defined as mutations present in the mother, but were undetectable or had DAF <2% in the child. Likewise, de
novo mutations were defined as those present in the child, but were undetectable or had DAF <2% in the mother. Transmitted mutations were
mutations shared between the mother and the child with DAF2%. The total number of untransmitted, transmitted and de novo mutations was
indicated in parentheses for mother-sibling pairs and mother-proband pairs in the legend. Error bars represent the 95% confidence interval of
the proportion estimated based on 10,000 bootstrap samples. CADD: mutations predicted pathogenic with CADD Phred score >15 or >20.
Results in the main text were based on “CADD > 15”; P: p values for Fisher’s exact test.
doi:10.1371/journal.pgen.1006391.g003
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30.8% among 39 children and 41.0% among their mothers [36]. Li et al. also identified a 41.0%
prevalence of heteroplasmy in the blood specimens from 139 individuals with an average age
of 58 [34]. Both studies employed mtDNA-targeted deep sequencing to sequencemtDNA to
an extremely high coverage, yielding sufficient power for detecting heteroplasmies with MAF
down to 1%. Using a similar design to our study, Ding et al. attained a 33.2% prevalence of het-
eroplasmy among 2,120 individuals with an average age of 47 years by analyzing the whole-
genome sequencing data of SardiNIA Project participants [38]. A 180X depth of average cover-
age was obtained on mtDNA. Ding et al. also noticed a considerable elevation of heteroplasmy
incidence among elderly Sardinians [38]. Hence, the prevalence of heteroplasmy among chil-
dren and young adults could be lower than 33.2%, which was close to our estimate of hetero-
plasmy prevalence at 21.1%. A 20–30% prevalence of medium-to-high fraction heteroplasmies
in bloodwas also verified by Sanger-based sequencing, showing that both the prevalence and
frequency spectrumof mtDNA heteroplasmies were largely comparable to results generated by
massively parallel sequencing [50].
The average depth of mtDNA coverage was significantly lower in mothers (132X [interquar-
tile range, IQR:96X-150X], t-test, P<0.0003) than that in siblings (142X [IQR:103X-162X])
and probands (148X [IQR:105X-166X]). This effect could be related to age-dependent decrease
of mtDNA copy number in blood [38], and could theoretically have influenced some results in
the study. However, the difference of mtDNA coverage between probands and siblings in this
dataset was minor and was not statistically significant (t-test, P = 0.074). To ensure such differ-
ences in mtDNA sequencing coverage did not confound our results, we performed a proof-of-
concept analysis by down-sampling the complete dataset to harmonize sequencing coverage in
the mother-proband-sibling trio of each family. In brief, we down-sampled reads of individuals
to the lowest depth sequenced in the mother-proband-sibling trio at each mtDNA site. This
procedure ensured that individuals from the same family had equal sequencing coverage at
everymtDNA site, thus eliminating the possible influence of distinct sequencing coverage on
heteroplasmy calling between different groups. Results from this analysis showed that a similar
number of heteroplasmies were detected from down-sampled reads compared to total reads in
all groups (S1 Text), indicating that lowering read counts in some individuals did not decrease
power to identify heteroplasmy differences among family members. The difference between
the complete and the down-sampled datasets among mothers, siblings, and probands was also
comparable to each other (Fisher’s exact test, P>0.34 for pair-wise comparisons, S1 Text).
Moreover, the enrichment of nonsynonymous and predicated pathogenic mutations in pro-
bands remained consistent in independent down-sampling analyses, close to the enrichment
level that we computed based on total reads (S9 Fig). Down-sampling reads in each family also
did not qualitatively alter the transmission pattern of heteroplasmies betweenmothers and
children (S1 Text). Overall, this test indicated that sequencing coverage differences between
mothers and children did not significantly bias heteroplasmy calling and comparisons in the
current study.
An extremely high transition-to-transversion ratio was among de novomutations in chil-
dren: only 4 out of the 210 de novo heteroplasmic mutations were transversion mutations
(three detected in probands and one detected in siblings). Such a mutation pattern is indicative
of mtDNA replication errors and thus early developmental effects, rather than mtDNA damage
caused by elevated oxidative stress associated with ASD [51]. Cell and animal studies [52,53] as
well as mitochondrial pathophysiology [31] studies have demonstrated that genetic defects in
OXPHOS genes culminate in elevated oxidative stress, inflammation, and metabolic abnormal-
ities. However, the impact of oxidative stress on mtDNA may prevail among low-fraction het-
eroplasmies and mtDNA deletions. Further studies using mtDNA-targeted deep sequencing
will enable us to systematically evaluate mtDNA mutation patterns in autistic patients.
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We found that autistic probands carried overrepresented heteroplasmic mutations at non-
polymorphicmtDNA sites, resulting in a ~1.5-fold enrichment of nonsynonymous mutations
(P = 0.0028) as well as a ~2.2-fold enrichment of predicted pathogenic mutations (P = 0.0016)
compared to those in non-autistic siblings (Fig 2C). The enrichment of predicted pathogenic
mutations in autistic probands was not affected by the pathogenicity scores used and was fur-
ther confirmed by the analysis of disease-associatedmutations (S4 Fig). These results point to
significant elevation of pathogenicity on mtDNA for autistic patients and thus provide a
molecular basis for mitochondria-related pathophysiological phenotypes, as well as the high
prevalence of MD among autistic patients [14,19].
In addition, we observed an overrepresented transmission of mtDNA mutations of high
pathogenic potential from the mother to the autistic proband (Fig 3 and S2 Table). Due to the
complete maternal inheritance of mtDNA [46,54], purifying selection in the maternal line may
retain pathogenic mutations that possess a highmitochondrial threshold in females but a low
mitochondrial threshold in males [55]. A recent study showed a male-biased expression profile
for mitochondria-related genes during early childhood and puberty in the human brain [56].
Accordingly, pathogenic mtDNA mutations may adversely impact brain functionwhen trans-
mitted from the mother to the male proband, possibly contributing to the observed sexual
dimorphismwhereby males are more susceptible to neurodevelopmental disorders [57].
Of interest, such a transmission pattern of ASD-associated variants is also evidenced by the
maternal transmission disequilibriumof nuclear LGD SNVs and rare CNVs in male autistic
probands, but is inconclusive in female probands [24]. We assume that there can be a similar
sex-dependent effect of pathogenic mtDNA heteroplasmies on ASD. Of the 903 families, there
were 815 and 88 families with male and female probands, respectively, for a ratio of male:
female of 9.3:1. A significant difference in transmission pattern was identified for nonsynon-
ymous and predicted pathogenic mtDNA heteroplasmies in male probands compared to that
in their siblings (ratio>1.3, one-tailed paired t-test, P<0.02, S2 Table), but no difference was
present in families with female probands (ratio = 1, S2 Table). In contrast, comparable trans-
mission patterns of mtDNA heteroplasmies to autistic probands were found when we stratified
families according to the sibling sex. Given that the sample size of female probands was rather
small in the current dataset, additional data on more ASD families with female probands
would be required to confirm this finding and potentially reveal other differences in mtDNA
heteroplasmy between families with male probands and families with female probands.
The majority (>65%) of mtDNA mutations detected in the current study had derived allele
fraction in the range of 5% to 20%, below the clinical threshold for most disease-causing het-
eroplasmies [42]. It is still elusive how low-to-medium fraction heteroplasmies affect mito-
chondrial function. Picard et al. found that cells harboring the mtDNA m.3243A>G
heteroplasmic mutation undergo a biphasic phenotypic change in response to the rise of het-
eroplasmy level; a medium heteroplasmy level (10%-30%) is presumed to cause mild OXPHOS
deficiency in Diabetes [58] and Autism [59], while a high heteroplasmy level (50%-90%) gives
rise to diverse, severe forms of neurodegenerative diseases such as mitochondrial encephalo-
myopathies [60]. Hence, individuals carrying a high degree of mtDNA heteroplasmies are
prone to manifest systematic symptoms of MD rather than behavioral signs of ASD. Indeed, it
is estimated that 10%-20% of MD patients have some autistic endophenotypes, further suggest-
ing a possible, shared etiology for these two diseases [19].
Some neurological and developmental pathologies of MD [61] are present in ASD patients,
including seizure, eating disorders, impaired motor ability and developmental delay [45,62,63].
Among the 33 autistic children detectedwith predicted pathogenic and/or disease-associated
private mtDNA mutations in the current study, whosemedical records were also available at
SFARI phenotype database, six were reported with febrile or non-febrile seizures and two were
Pathogenic mtDNA Heteroplasmy and Autism
PLOS Genetics | DOI:10.1371/journal.pgen.1006391 October 28, 2016 12 / 24
diagnosedwith epilepsy (S3 Table). One autistic child was found to have anorexia nervosa and
the other two were reported with movement abnormalities (S3 Table). Early signs of metabolic
or developmental defects related to MD [64] in these 33 autistic children included neonatal
hypotonia (n = 3) and hypoglycemia (n = 3) (S3 Table), both of which were identified as risk
factors for ASD [65,66]. Medical records also revealed a significantly higher incidence of men-
tal retardation among the 33 autistic children than that in the rest of the database (Fisher’s
exact test, P = 0.048, S3 Table), in line with our findings on the negative association between
pathogenic mtDNA mutations and IQ. The overall prevalence of aforementioned abnormali-
ties was 1.2 times higher in these 33 autistic children than other autistic children included in
this study as well as in the rest of the SFARI database (36.4% vs. 16.7%, Fisher’s exact test,
P<0.008, S3 Table). Furthermore, a decrease in height was found among these autistic children
compared to other autistic children in the SFARI database (Mann-Whitney test, P = 0.026, S3
Table). Shorter stature was previously proposed as one of the major symptoms of MD [61,67]
and was discovered in patients with mtDNA(m.3243A>G) heteroplasmy-caused diabetes (i.e.
maternally inherited diabetes and deafness, MIDD) compared to non-MIDD diabetic patients
such as patients diagnosedwith type 1 or type 2 diabetes [68], suggesting a common underlying
pathophysiology of mtDNA origin. Taken together, these evidence indicate that pathogenic
mtDNA mutations may be responsible for a wide range of developmental abnormalities in chil-
dren which confer susceptibility to ASD. It also calls attention to ASD children with one or
more developmental abnormalities or related co-morbid clinical conditions for further testing
on mtDNA and mitochondrial defects.
In sum, our findings support the connection betweenmtDNA variation and ASD, and call
on furthermtDNA-targeted deep sequencing and functional studies in more ASD families,
which are of great importance to understandmtDNA mutation patterns and their contribution
to ASD-related phenotypes. Indeed, mitochondrial dysfunction has been implicated in many
childhooddisorders, especially neurodevelopmental disorders [69]. These diseasesmanifest
metabolic and physiological phenotypes that converge upon mitochondrial dysfunction, and
may have mtDNA defects as a common harbinger. Further understanding the genetic architec-
ture of mitochondrial genome in these phenotypes will provide crucial insights into pathogene-
sis, diagnosis, and treatment of these diseases.
Materials and Methods
Study samples and sequencing data
We downloaded the whole-exome sequencing data for 1,905 simplex families from the
National Database for Autism Research (NDAR) under the study DOI:10.15154/1149697 (last
accessedNov. 2015). The raw sequencing data were generated by three genome centers includ-
ing CSHL (n = 933), YALE (n = 599) and UW (n = 373). Only reads generated by CSHL had
sufficient coverage on mtDNA (S1 Fig). We obtained similar results using alignment files gen-
erated from the same exome sequencing data set by Krumm et al. [24]. A possible explanation
for such discrepancy of mtDNA coverage across different genome centers might lie in the dif-
ferent exome capturing protocol and sequencing read length used by each center [23,40].
Hence, we analyzed the 933 families sequenced at CSHL.We retrieved pertinent sample phe-
notypes including sex, ethnicity, age, full-scale intelligence quotient scores, Social Responsive-
ness Scale scores, and medical records from the supplementary data of previous publications
on the SFARI Simons Collection [23,70], the sample information sheet available at NDAR,
and/or the SFARI phenotype database (version 15).
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Sequencing data processing
We first extracted sequencing read pairs mapped to mtDNA from the downloaded alignment
files. In order to filter out reads resulting from nuclear mitochondrial sequences (NUMTs),
extracted reads were realigned to the complete human reference genome consisting of both
human nuclear DNA and mtDNA sequences by using BWA (version 0.7.2) [71]. The reference
sequences of the GRCh38 human genome assembly were obtained from the 1000Genomes
project ftp site [41]. Reads mapped to the nuclear DNA were removed. Next, we performed a
series of data processing steps to ensure the quality of remaining reads for callingmtDNA
homoplasmies and heteroplasmies, including (1) local realignment around indels; (2) base
quality recalibration; (3) detection and exclusion of duplicated reads, reads shorter than 40 bp,
reads with5%mismatches, as well as reads that were not aligned in a pair on mtDNA. The
remaining reads were then piled up against the revisedCambridge Reference Sequence (rCRS)
by using “samtool mpileup” with a mapping quality filter at 20 [72]. The list of tools and spe-
cific commands employed in each step was detailed in S10 Fig. A comparison of methods for
heteroplasmy calling with previous studies was given in S4 Table.
Point homoplasmy and heteroplasmy calling
To reduce the false positive rate, we only considered reads with a recalibrated base quality
Phred score20 (tantamount to0.01 sequencing error) for calling point homoplasmies and
heteroplasmies. For homoplasmy, the alternative allele according to rCRSmust be supported
by at least 10 reads and not be in the heteroplasmic state. Criteria for calling heteroplasmies
encompassed (1)>40X depth of coverage, (2) the alternative allele being observedon both
strands, and (3) comparable allele fractions calculated from reads mapped to two strands (Fish-
er’s exact test, P0.01). We also required that an mtDNA site was valid for calling heteroplas-
mies if its median site coverage was>70X depth in the study population. Based on one-tailed
power calculation for one sample proportion test, it yielded>90% power of detecting real het-
eroplasmies with minor allele fraction (MAF) 5% over 1% sequencing error (S11 Fig). As a
result, we obtained a total of 12,180 candidate heteroplasmies from 13,704 valid mtDNA sites
(83% of total mtDNA sites, S5 Table and S12 Fig).
Maximum likelihood based approach for estimating heteroplasmy
fraction
Next, we utilized a maximum likelihoodbased approach to estimate MAF for each hetero-
plasmy by taking into account the base quality information of covered reads [37,40]. In brief,
the likelihood of observingn reads with the minor allele and m reads with the major allele at a
particular site was computed as:
L ðf jmapped readsÞ ¼
Yn
i¼1
ðð1   f Þεi þ f ð1   εiÞÞ
Ym
i¼1
ðð1   f Þð1   εiÞ þ f εiÞ
, where f refers to the MAF of interest and εi is the corresponding sequencing error for mapped
read i. We then took the maximum-likelihoodestimate of f and calculated the log likelihood
ratio between the heteroplasmic model and the homoplasmic model (LLR = log(L(f^ )/L(f^0))).
LLR score>5 was used as a criterion to define heteroplasmies of high confidence, equivalent to
a false positive rate<10−5 [40].
Of heteroplasmies detectedwith MAF5% at valid sites, over 98% had a LLR score over 5
(S13 Fig), which was consistent with our power calculation. In addition to insufficient sequenc-
ing depth, heteroplasmies with a low LLR score can also result from sequencing error or
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complications from nuclear mitochondrial sequences (NUMTs). Both give rise to a much
lower transition-to-transversion (Ti/Tv) ratio compared to real heteroplasmies on mtDNA,
which predominantly arise frommutations caused by endogenous, mtDNA polymerase repli-
cation errors [51]. When filtered at MAF5%, high-confidenceheteroplasmies yielded a Ti/
Tv ratio of 29.5, in line with the hypothesizedmutation pattern of mtDNA. High-confidence
heteroplasmies could be recovered with the LLR score filter>5 down to MAF = 2% (greater
than the base quality error threshold 1% used), which had a Ti/Tv ratio comparable to that of
heteroplasmies with MAF5% (22.8 vs. 29.5; chi-square test P = 0.5; S6 Table). But the major-
ity of low-fraction heteroplasmies (MAF<5%) were probably missing due to insufficient
sequencing depth.
Sample quality control
We first removed 19 samples with average mtDNA coverage40X depth. To minimize DNA
contamination problems, we further removed samples (n = 19) if they had (1)>5 heteroplas-
mies located at polymorphic mtDNA sites in this population and/or (2)>50% of heteroplas-
mies detectable as homoplasmies in another sample, which also accounted for>50% of
homoplasmic sites in that particular sample distinct from those in the sample under investiga-
tion. Contamination detectionwas based on high-confidenceheteroplasmies with MAF2%.
903 (97.1%) families with sequencing data from the proband, the sibling and the mother
remained and were used for further analysis. The exome sequencing data from the father were
processed using the same method but were only utilized for exploring data quality and detect-
ing sample contamination. The average depth of mtDNA coverage in the remaining samples
was ~141X, comparable to the coverage reported in previous studies using whole-exome or
whole-genome sequencing data [38,39,73]. Comparisons of site-specific sequencing coverage
for homoplasmic and heteroplasmic sites also showed strong correlations between individuals
within the same family (R2>0.6, S14 Fig).
After sample quality control, we obtained 677 high-confidenceheteroplasmies with MAF
5% in 903 families (S1 Dataset).We checked the mtDNA site for each of the 677 heteroplas-
mies within the family where it was found. 649 of them (95.9%) were located at mtDNA sites
(n = 447) where all members from a family had>40X sequencing depth and thus were used
for comparing incidence and studying transmission pattern of heteroplasmies (S1 Dataset).
We further defined the major allele in a family, the allele with the highest fraction in the
mother-proband-sibling trio, as the reference allele for each site on the consensus sequence,
and considered a heteroplasmy inherited if the reference allele and the derived allele in the
child were detected in the mother with fraction2%. Otherwisewe considered it de novo in
the child.
Annotation of mtDNA variants
mtDNA variants were annotated by using the ANNOVAR pipeline [74]. Pathogenicity predic-
tions for all possible mtDNA nucleotide substitutions according to the revised Cambridge Ref-
erence Sequence (rCRS) were retrieved from the CADD database (version 1.3). The CADD
score is a composite matric for deleteriousness of human mutations obtained through agglom-
erating annotation information from 63 distinct sources, which outperforms most popular
pathogenicity predictors such as PolyPhen-2 and SIFT [75]. We followed the recommended
cutoff for the scaled CADD score at 15 to define pathogenic mutations and used a more strin-
gent cutoff at 20 for sensitivity testing. Alternative pathogenicity scores were also used for veri-
fication, including PolyPhen-2 [76], Mutation Assessor [77] and MutPred [78]. PolyPhen-2
scores and Mutation Assessor scores were extracted from the MitImpact2 database (version
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2.4) [79], and MutPred scores were retrieved from a previous study [43]. All of them generated
pathogenicity scores comparable to CADD scores (S15 Fig). A list of disease-associated,nonsy-
nonymous and RNA mutations was compiled according to the MITOMAP website [80] and
the ClinVar database [81] (last accessed Jan. 2016). Mutations with ambiguous annotations
such as “unclear”, “conflicting reports” or “further studies needed”, or listed as “synergistic” or
“secondary” on the MITOMAP website were not included. Both position and mutant allele
information were used for definingmutations. In addition, we constructed a list of mutations
which were predicted pathogenic by at least two of the five pathogenicity predictors: (1) CADD
Phred score>15; (2) PolyPhen-2 possible and probable damaging; (3) Mutation Assessor
medium and high impact; (4) MutPred score>0.6; (5) associated with disease.We relied on
this list of mutations to replicate results from analyses using only CADD scores. Related results
were denoted as “combined prediction” in S4 Fig, S5 Fig and S9 Fig.
mtDNA haplogroups
The mtDNA haplogroup information was assessed by using HaploGrep2 [82]. The resulting
distribution of macro-haplogroups among the 903 families was representative of that among
the U.S. population [83] (S7 Table). The concordance rate between the mtDNA-inferred ances-
tral lineage and self-reportedmaternal ethnicity or race was>96.8% in non-admixed popula-
tions including non-Hispanic white (n = 654) and Asian (n = 49) (S7 Table), in close
agreement with the concordance rate recently reported for the NHANES study [83] and
among 588 mtDNA-sequenced individuals [84].
Statistical testing
Incidence of mtDNA mutations between probands and siblings was compared at a family level
by using paired t-test. Differences in transmission pattern in mother-autistic proband pairs
and mother-sibling pairs were assessed by using Fisher’s exact test. Other statistical methods,
such as correlation test, ANOVA, linear regression and logistic regression, were also used as
indicated in the text. Statistical testing in this study was carried out by using R (version 3.2.2)
and python (version 2.7.5)/scipy (version 0.16.1).
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S2 Fig. Incidence of mtDNA homoplasmies and heteroplasmies. (A) Incidence of mtDNA
homoplasmies. MAF: minor allele frequency of homoplasmies. Site-specific incidence of
homoplasmies was given in S2 Dataset. (B, C) Incidence of mtDNA heteroplasmies with minor
allele fraction5% and confidence score>5.
(TIFF)
S3 Fig. Relative mutation rates of mtDNA variants.The box plot of relative mutation rates for
heteroplasmies at non-polymorphic sites, heteroplasmies at polymorphic sites and homoplasmies
at non-heteroplasmic sites. The relative mutation rate for each nucleotide substitution on
mtDNA was previously estimated by counting the number of times each nucleotidemutated
independently in the phylogenetic tree representing the global human mtDNA variation [44].
The relative mutation rates for all observed substitutions as well as observednonsynonymous
substitutions were shown. Outliers were not depicted for clarity. Each nucleotide substitution
was only counted at most once. P<7x10-23; P<6x10-3; P: p values for Mann-Whitney test.
(TIFF)
S4 Fig. Comparison of pathogenicmutation burden between autistic probands and non-
autistic siblings.Mutation burden was calculated using mutations with DAF 5% at mtDNA
sites where all members in a family had>40X sequencing depth. Error bars represent the stan-
dard error of the mean. NS: nonsynonymous mutations; CADD: mutations with CADD Phred
score>15 or>20; PolyPhen-2: possible and probable damagingmutations predicted by Poly-
Phen-2; Mutation Assessor: medium and high impact mutations predicted by Mutation Asses-
sor;MutPred: mutations with MutPred score>0.6; disease-associated:nonsynonymous or
RNA mutations associated with disease according to the MITOMAP website and the ClinVar
database; combined prediction:mutations predicted pathogenic in at least two of the five afore-
mentioned pathogenicity categories (detailed in Materials and Methods). P: p values for one-
tailed paired t-test.
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S5 Fig. Differential ratio of pathogenicmtDNA mutations between probands and siblings
under varyingDAF thresholds.The ratio of mtDNA mutations between probands and sib-
lings is shown in (A) for nonsynonymous mutations, in (B,C) for mutations predicted
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pathogenic with CADD Phred score>15 or>20, and in (D) for mutations predicted patho-
genic in at least two of the five pathogenicity categories (detailed in Materials and Methods).
The black circles in each figure refer to the observed ratios of mtDNA mutations between autis-
tic probands and non-autistic siblings under varying thresholds of minimumDAF (from 2% to
8%) for definingmutations. The pink area represents 90% confidence interval of the same ratio
estimated based on 10,000 bootstrap samples of the 903 families.
(TIFF)
S6 Fig. Association between private mtDNA mutations and IQ. Associations of IQ with pro-
band-private mtDNA mutations were computed in 638 probands of the major ethnic group
among the 903 families who had a reported family ancestry of “white” or “more-than-one-race”
and an mtDNA-haplogroup inferredmaternal ancestry of “Europe”. Boxplots of IQ were
depicted according to proband-private (A) mutations at non-polymorphic sites, (B) mutations at
polymorphic sites, (C) nonsynonymous mutations, (D,E) mutations predicted pathogenic based
on CADD Phred score>15 or>20, and (F) disease-associatedmutations. The dashed red lines
indicate a IQ of 70. Coefficients (Beta,β) and significance levels (P) of the associations between
proband-private mtDNA mutations and IQ were given in the Table below the boxplots based on
results from linear regressionModel 1 (adjusting for age and sex) and Model 2 (adjusting for age,
sex, SRS scores and whether carryingde novo LGD SNPs or CNVs on nuclear DNA).
(TIFF)
S7 Fig. Proportion of inherited heteroplasmies in children.The proportion of heteroplas-
mies could be detected in the mother with DAF 2%.
(TIFF)
S8 Fig. Changes of derived allele fractions of mtDNA mutations in mother-sibling pairs
andmother-proband pairs.Changes of derived allele fractions (ΔDAF = DAFchild−DAFmother)
of mtDNA mutations were depicted in A, C, E, and G for mother-sibling pairs (blue), and in B,
D, F, and H for mother-proband pairs (red). Only mtDNA sites (n = 448) detectedwith high-
confidence heteroplasmies (MAF5%) or de novo homoplasmies were used for calculation.
The total number of mutations used for plotting was indicated in parentheses under each fig-
ure. CADD: mutations with CADD Phred score>15 or>20.
(TIFF)
S9 Fig. Differential ratio of pathogenicmtDNA mutations computed after down sampling
reads in each family. The ratio of mtDNA mutations between probands and siblings is shown
in (A) for nonsynonymous mutations, in (B,C) for mutations predicted pathogenic with
CADD Phred score>15 or>20, and in (D) for mutations predicted pathogenic in at least two
of the five pathogenicity categories (detailed in Materials and Methods). The open circles and
lines in each figure indicate the ratios of mtDNA mutations between autistic probands and
non-autistic siblings computed using total reads under varying thresholds of minimumDAF
(from 2% to 8%) for definingmutations. The filled circles, squares, and triangles refer to the
same ratios of mtDNA mutations between autistic probands and non-autistic siblings com-
puted from three independent down-sampling procedures to harmonize mtDNA sequencing
coverage in the mother-proband-sibling trio of each family. The statistical significance that the
ratio is greater than one (P for one-tailed paired t-test) is shown using different colors indicated
in the legend on the right side.
(TIFF)
S10 Fig. Data processing workflow.
(TIFF)
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S11 Fig. Power calculation for heteroplasmy calling.Results were obtained from one-tailed
power calculation for one sample proportion test of discriminating real heteroplasmies from
sequencing errors under the assumption of base quality error1% (~0.33% for each possible
substitution). Each curve refers to the power for detecting heteroplasmies with increasingMAF
using the sequencing depth indicated in the legend.
(TIFF)
S12 Fig. Genomic distribution of mtDNA heteroplasmies.The 677 high-confidence,
median-to-high fraction heteroplasmies (MAF5%) were depicted with their positions on the
mitochondrial genome indicated on the X axis, and their minor allele fractions indicated on
the Y axis on the right hand side. Heteroplasmies detected in mothers, siblings, and probands
were depicted using squares, triangles and diamonds, respectively. Heteroplasmies in grey are
transitions and heteroplasmies in red are transversions. The black curve represents the median
sequencing coverage for each mtDNA site as indicated on the Y-axis on the left hand side.
Both of Y axes are on logarithmic scales. Fluctuation of sequencing coverage is due to complex-
ity of the mitochondrial genome and its sequence similarity with baits designed for whole
exome sequencing [40]. The middle panel displays the exact positions (black) of the 13,704
mtDNA sites valid for calling heteroplasmies. The lower panel displays the D-loop region
(grey), the 24 RNA genes (blue), and the 13 protein-coding genes (red) on the mitochondrial
genome.
(TIFF)
S13 Fig. Distribution of confidence scores among candidate heteroplasmies.The 12,180
candidate heteroplasmies were detected from 13,704 mtDNA sites valid for calling heteroplas-
mies. The cumulative distributions of LLR scores for heteroplasmies were shown in the above
figures stratified by the minor allele fraction.
(TIFF)
S14 Fig. Correlations of site coverage at homoplasmic and heteroplasmic sites between
individualswithin each family. The regression lines were depicted in red.
(TIFF)
S15 Fig. Comparisons betweenCADD predictions and other pathogenicity predictions on
mtDNA mutations. For all predictors, the higher the pathogenicity score of a nucleotide sub-
stitution, the greater the chance it is pathogenic. P<2x10-100.
(TIFF)
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